Review

Not peer-reviewed version

Systemic Leaky Barrier Syndrome (SLBS): A Systems-Level Framework for Chronic Disease

Richard Z. Cheng *

Posted Date: 3 February 2026

doi: 10.20944/preprints202602.0069.v2

Keywords: biological barriers; intestinal permeability; blood–brain barrier; endothelial dysfunction; systemic inflammation; redox stress; chronic disease; cancer metastasis

 doi:10.20944/preprints202602.0069.v2

Review

Systemic Leaky Barrier Syndrome (SLBS): A Systems-Level Framework for Chronic Disease

Richard Z. Cheng [1,2]

[1] Cheng Integrative Health Center, Columbia, SC, USA; richzc@gmail.com
[2] Cheng Health Consulting, Ltd., Shanghai, China

Abstract

Systemic Leaky Barrier Syndrome (SLBS) is a conceptual framework in which *loss of integrity across multiple biological barriers* — intestinal, vascular, blood–brain, pulmonary, renal, and skin — is driven by shared *structural, metabolic, and inflammatory mechanisms*. This hypothesis unifies disparate chronic diseases and aging processes by focusing on common upstream drivers (oxidative stress, micronutrient insufficiency, mitochondrial dysfunction, and chronic inflammation) that impair tight junctions and cell–matrix adhesion across tissues. SLBS reframes chronic disease not as isolated organ dysfunction, but as *systemic failure of barrier integrity*, with clinical implications for early detection, prevention, and integrative therapeutic strategies. This framework also has implications for cancer progression, where invasion and metastasis require coordinated failure of multiple host barrier systems.

Keywords: biological barriers; intestinal permeability; blood–brain barrier; endothelial dysfunction; systemic inflammation; redox stress; chronic disease; cancer metastasis

---

1. Introduction: Biological Barriers and the Paradox of Permeability

Biological barriers are fundamental anatomical and functional interfaces that maintain compartmentalization while regulating essential transport. At a cellular level, this is achieved by *tight junctions* and related junctional complexes in epithelial and endothelial tissues that prevent uncontrolled paracellular flux and preserve tissue homeostasis.

Tight junctions (TJs) are multiprotein complexes that prevent leakage between adjacent cells and are central to barrier function in gut, vasculature, kidney, and the blood–brain barrier (BBB)[1].

The **blood–brain barrier** is a classic example of a highly selective barrier formed by endothelial cells interconnected by tight junctions, astrocytic support, and pericytes, restricting the passage of solutes and immune factors from blood into the central nervous system[1].

Similarly, the **intestinal barrier** integrates epithelial, mucosal, immune, and vascular elements to regulate nutrient absorption and prevent translocation of microbes and antigens[2].

2. SLBS Defined

Systemic Leaky Barrier Syndrome (SLBS) is the condition in which systemic environmental, metabolic, and inflammatory stressors compromise the integrity of barrier systems across organs. Rather than isolated "leaky gut" alone, SLBS posits that a *network of barrier dysfunctions* synergize to drive chronic diseases:

- **Intestinal permeability** → immune activation and bacterial translocation.
- **Endothelial barrier loss (vasculature, glyco-calyx)** → atherogenesis and thrombosis.
- **Blood–brain barrier disruption** → neuroinflammation and cognitive disorders.
- **Pulmonary barrier compromise** → ARDS and chronic airway disease.
- **Renal filtration failure** → proteinuria and CKD progression.
- **Skin barrier dysfunction** → inflammatory dermatoses.

 doi:10.20944/preprints202602.0069.v2

This systemic perspective arises from *shared molecular mechanisms* that govern barrier assembly and repair.

3. Systemic "Leaky" Barriers Documented in the Literature

Systemic barrier dysfunction has been described across multiple organ systems in the biomedical literature. Although these phenomena are typically examined within organ-specific disciplines, they share common structural and molecular features. Representative examples of barrier permeability ("leakiness") across major organ systems are summarized below to illustrate the systemic nature of barrier failure.

3.1. Leaky Gut (Intestinal Barrier)

Barrier: Intestinal epithelium (tight junctions, mucus layer)
Clinical relevance: Autoimmunity, metabolic disease, ASD, chronic inflammation[3,4]

3.2. Leaky Brain (Blood–Brain Barrier, BBB)

Barrier: Cerebral endothelial tight junctions + astrocytes + pericytes
Clinical relevance: ASD, neurodegeneration, stroke, neuroinflammation[5]

3.3. Leaky Vasculature / Endothelium (Including Glycocalyx)

Barrier: Endothelial cell junctions and glycocalyx
Clinical relevance: ASCVD, hypertension, thrombosis, sepsis, long COVID[6,7]

3.4. Leaky Lung (Alveolar–Capillary Barrier)

Barrier: Alveolar epithelium + pulmonary endothelium
Clinical relevance: ARDS, asthma, COVID-19, pulmonary edema[8,9]

3.5. Leaky Kidney (Glomerular Filtration Barrier)

Barrier: Glomerular endothelium + basement membrane + podocytes
Clinical relevance: Proteinuria, CKD, diabetic nephropathy[10,11]

3.6. Leaky Eye (Blood–Retinal Barrier)

Barrier: Retinal endothelial and epithelial tight junctions
Clinical relevance: Diabetic retinopathy, macular degeneration, inflammation[12,13]

3.7. Leaky Skin (Epidermal Barrier)

Barrier: Stratum corneum + tight junctions
Clinical relevance: Atopic dermatitis, allergy, immune dysregulation[14,15]

3.8. Leaky Placenta (Placental Barrier)

Barrier: Trophoblast layers + endothelial interfaces
Clinical relevance: Fetal programming, neurodevelopmental risk[16]

3.9. Leaky Liver (Sinusoidal Endothelium)

Barrier: Fenestrated hepatic sinusoidal endothelial cells
Clinical relevance: NAFLD, systemic inflammation, endotoxemia[17,18]
Synthesis statement:

Loss of barrier integrity is not confined to a single organ system. Intestinal, vascular, blood–brain, pulmonary, renal, retinal, cutaneous, placental, and hepatic barriers share common molecular

 doi:10.20944/preprints202602.0069.v2

dependencies, including tight junction integrity, redox balance, mitochondrial energy supply, and inflammatory control.

4. Shared Mechanisms of Barrier Dysfunction

4.1. Tight Junctions and Cell–Cell Adhesion

Tight junction proteins (e.g., occludin, claudins, ZO-1) are essential to barrier integrity. Their loss or dysregulation correlates with increased paracellular permeability in many diseases[19].

BBB tight junction complexes are particularly well studied; disruption correlates with stroke, neurodegeneration, and neuroinflammation[20].

4.2. Systemic Inflammation and Redox Stress

Barrier function is sensitive to inflammatory cytokines and oxidative stress, which can disrupt cytoskeletal support for junctions and activate matrix metalloproteinases that degrade extracellular matrix. Chronic inflammation fuels a vicious cycle of barrier breakdown and immune activation that is *not confined to one organ*[21].

The mechanisms underlying Systemic Leaky Barrier Syndrome (SLBS) overlap substantially with previously proposed systems-level root driver models of chronic disease, including environmental, metabolic, nutritional, inflammatory, mitochondrial, and psychosocial stressors that converge on structural tissue integrity and repair capacity[22].

4.3. Micronutrient and Metabolic Dependencies

Micronutrients — particularly vitamin D — are required for proper expression of tight junction proteins and barrier competence. Vitamin D deficiency exacerbates gut and extra-intestinal barrier dysfunction in animal models and is associated with worsened inflammatory phenotypes[23].

Although more studies are needed, antioxidant systems (e.g., glutathione, vitamin C) and mitochondrial ATP production are fundamental to barrier maintenance and repair.

5. SLBS Across Clinical Phenotypes

SLBS provides a *common logic* for multiple chronic conditions:

- **Metabolic and cardiovascular disease:** Impaired endothelial junctions and glycocalyx damage promote leukocyte adhesion, lipid infiltration, and plaque genesis.
- **Autoimmunity and chronic inflammation:** Barrier leakage allows persistent antigen trafficking and immune dysregulation.
- **Neurological disorders:** BBB disruption enables peripheral cytokines and toxins to affect CNS function.
- **Gastrointestinal disorders:** Gut permeability facilitates microbial product translocation, fueling systemic inflammation and metabolic dysregulation.

Across these pathways, barrier dysfunction functions both as an initiating factor and an amplifier of disease progression.

5.1. Systemic Barrier Failure in Cancer Invasion and Metastasis

Cancer invasion and metastasis represent a pathological extreme of systemic barrier failure. While cancer is often framed primarily as a genetic or cellular disease, successful tumor dissemination requires coordinated breakdown of multiple host barriers, a process that aligns closely with the core principles of Systemic Leaky Barrier Syndrome (SLBS).

At the local tissue level, malignant progression is associated with disruption of epithelial integrity and basement membrane architecture. Loss of tight junction proteins, activation of matrix metalloproteinases, and epithelial–mesenchymal transition (EMT) enable tumor cells to breach

 doi:10.20944/preprints202602.0069.v2

structural barriers that normally constrain cellular migration and compartmentalization[24,25]. These processes mirror the junctional and extracellular matrix vulnerabilities described in SLBS across non-malignant tissues.

Beyond the primary tumor, vascular endothelial barrier dysfunction is essential for both intravasation and extravasation of circulating tumor cells. Tumor-associated angiogenesis is characterized by abnormal, highly permeable vasculature driven by inflammatory cytokines and vascular endothelial growth factor (VEGF), resulting in impaired endothelial junctions and glycocalyx degradation[26,27]. This leaky vascular phenotype facilitates tumor cell trafficking and mirrors endothelial barrier failure observed in cardiovascular and inflammatory diseases within the SLBS framework.

Immune barrier failure further contributes to metastatic progression. Chronic inflammation, immune exhaustion, and impaired immunosurveillance allow malignant cells to evade clearance while promoting a permissive microenvironment for barrier degradation. These immune–barrier interactions are consistent with SLBS-associated cycles of inflammation-induced permeability and permeability-driven immune dysregulation[28].

At distant sites, successful metastasis requires traversal of organ-specific barriers, including pulmonary, hepatic, and blood–brain barriers. Brain metastasis, in particular, exemplifies the requirement for blood–brain barrier disruption prior to tumor colonization, a process mediated by inflammatory signaling, endothelial junctional remodeling, and oxidative stress[29,30]. Such phenomena further support the view that metastasis reflects systemic, not merely local, barrier vulnerability.

Importantly, many upstream drivers implicated in SLBS—chronic inflammation, oxidative stress, mitochondrial dysfunction, and micronutrient insufficiency—are also well-recognized contributors to cancer progression and metastatic competence. From this perspective, metastasis can be reframed not solely as an emergent property of tumor cells, but as a consequence of compromised host barrier resilience.

Thus, SLBS provides a unifying systems-level lens through which cancer invasion and metastasis may be understood as manifestations of systemic multi-barrier failure, integrating tumor biology with host structural, metabolic, and inflammatory terrain.

6. Integrative Implications

SLBS reframes chronic disease management toward:

- Barrier-centric biomarkers
- Foundational interventions that support redox balance, micronutrient sufficiency, mitochondrial energy, and inflammation control
- Reduced reliance on symptom suppression alone

This does not replace disease-specific strategies but complements them by addressing upstream resilience and structural integrity.

7. Conclusion

Biological barriers are inter-organ gatekeepers whose integrity is essential for systemic homeostasis. SLBS posits that shared mechanisms of barrier breakdown underlie diverse chronic diseases. While empirical validation is ongoing, integrating established barrier biology with clinical perspectives offers a powerful conceptual lens for research and therapy.

References

1. Gawdi, R.; Shumway, K.R.; Emmady, P.D. Physiology, Blood Brain Barrier. In *StatPearls*StatPearls Publishing, Treasure Island (FL), 2025.; Available online: http://www.ncbi.nlm.nih.gov/books/NBK557721/.

 doi:10.20944/preprints202602.0069.v2

2. Portincasa, P.; Bonfrate, L.; Khalil, M.; et al. Intestinal Barrier and Permeability in Health, Obesity and NAFLD. *Biomedicines* 2021, *10*, (1). DOI: 10.3390/biomedicines10010083; Available online: https://www.mdpi.com/2227-9059/10/1/83.
3. Suliman, H.B.; Babiker, A.; Withers, C.M.; et al. Nitric Oxide Synthase-2 Regulates Mitochondrial Hsp60 Chaperone Function during Bacterial Peritonitis in Mice. *Free Radic Biol Med* 2010, *48*, (5), 736–746. DOI: 10.1016/j.freeradbiomed.2009.12.019.
4. Camilleri, M. Leaky Gut: Mechanisms, Measurement and Clinical Implications in Humans. *Gut* 2019, *68*, (8), 1516–1526. DOI: 10.1136/gutjnl-2019-318427.
5. Abbott, N.J.; Rönnbäck, L.; Hansson, E. Astrocyte–Endothelial Interactions at the Blood–Brain Barrier. *Nat Rev Neurosci* 2006, *7*, (1), 41–53. DOI: 10.1038/nrn1824; Available online: https://www.nature.com/articles/nrn1824.
6. Pries, A.R.; Kuebler, W.M. Normal Endothelium. *Handb Exp Pharmacol* 2006, (176 Pt 1), 1–40. DOI: 10.1007/3-540-32967-6_1.
7. Chelazzi, C.; Villa, G.; Mancinelli, P.; et al. Glycocalyx and Sepsis-Induced Alterations in Vascular Permeability. *Crit Care* 2015, *19*, (1), 26. DOI: 10.1186/s13054-015-0741-z.
8. Ware, L.B.; Matthay, M.A. The Acute Respiratory Distress Syndrome. *New England Journal of Medicine* 2000, *342*, (18), 1334–1349. DOI: 10.1056/NEJM200005043421806; Available online: https://www.nejm.org/doi/full/10.1056/NEJM200005043421806.
9. Bhattacharya, J.; Matthay, M.A. Regulation and Repair of the Alveolar-Capillary Barrier in Acute Lung Injury. *Annu Rev Physiol* 2013, *75*, 593–615. DOI: 10.1146/annurev-physiol-030212-183756.
10. Haraldsson, B.; Nyström, J.; Deen, W.M. Properties of the Glomerular Barrier and Mechanisms of Proteinuria. *Physiol Rev* 2008, *88*, (2), 451–487. DOI: 10.1152/physrev.00055.2006.
11. Tryggvason, K.; Wartiovaara, J. How Does the Kidney Filter Plasma? *Physiology (Bethesda)* 2005, *20*, 96–101. DOI: 10.1152/physiol.00045.2004.
12. Cunha-Vaz, J.G. The Blood-Retinal Barriers System. Basic Concepts and Clinical Evaluation. *Exp Eye Res* 2004, *78*, (3), 715–721. DOI: 10.1016/s0014-4835(03)00213-6.
13. Campbell, M.; Humphries, P. The Blood-Retina Barrier: Tight Junctions and Barrier Modulation. *Adv Exp Med Biol* 2012, *763*, 70–84.
14. Elias, P.M. Skin Barrier Function. *Curr Allergy Asthma Rep* 2008, *8*, (4), 299–305. DOI: 10.1007/s11882-008-0048-0.
15. De Benedetto, A.; Rafaels, N.M.; McGirt, L.Y.; et al. Tight Junction Defects in Patients with Atopic Dermatitis. *J Allergy Clin Immunol* 2011, *127*, (3), 773-786.e1–7. DOI: 10.1016/j.jaci.2010.10.018.
16. Reynolds, L.P.; Dahlen, C.R.; Ward, A.K.; et al. Role of the Placenta in Developmental Programming: Observations from Models Using Large Animals. *Anim Reprod Sci* 2023, *257*, 107322. DOI: 10.1016/j.anireprosci.2023.107322.
17. Shetty, S.; Lalor, P.F.; Adams, D.H. Liver Sinusoidal Endothelial Cells - Gatekeepers of Hepatic Immunity. *Nat Rev Gastroenterol Hepatol* 2018, *15*, (9), 555–567. DOI: 10.1038/s41575-018-0020-y.
18. Poisson, J.; Lemoinne, S.; Boulanger, C.; et al. Liver Sinusoidal Endothelial Cells: Physiology and Role in Liver Diseases. *J Hepatol* 2017, *66*, (1), 212–227. DOI: 10.1016/j.jhep.2016.07.009.
19. Pober, J.S.; Sessa, W.C. Inflammation and the Blood Microvascular System. *Cold Spring Harb Perspect Biol* 2014, *7*, (1), a016345. DOI: 10.1101/cshperspect.a016345.
20. Liu, W.-Y.; Wang, Z.-B.; Zhang, L.-C.; et al. Tight Junction in Blood-Brain Barrier: An Overview of Structure, Regulation, and Regulator Substances. *CNS Neurosci Ther* 2012, *18*, (8), 609–615. DOI: 10.1111/j.1755-5949.2012.00340.x.
21. Dmytriv, T.R.; Storey, K.B.; Lushchak, V.I. Intestinal Barrier Permeability: The Influence of Gut Microbiota, Nutrition, and Exercise. *Front Physiol* 2024, *15*, 1380713. DOI: 10.3389/fphys.2024.1380713.
22. Cheng, R.Z. From Mutation to Metabolism: Root Cause Analysis of Cancer's Initiating Drivers. *Preprints* 2025, 2025090903. DOI: 10.20944/preprints202509.0903.v1; Available online: https://www.preprints.org/manuscript/202509.0903/v1.

 doi:10.20944/preprints202602.0069.v2

23. DiGuilio, K.M.; Rybakovsky, E.; Abdavies, R.; et al. Micronutrient Improvement of Epithelial Barrier Function in Various Disease States: A Case for Adjuvant Therapy. *Int J Mol Sci* 2022, *23*, (6), 2995. DOI: 10.3390/ijms23062995.
24. Lu, P.; Weaver, V.M.; Werb, Z. The Extracellular Matrix: A Dynamic Niche in Cancer Progression. *J Cell Biol* 2012, *196*, (4), 395–406. DOI: 10.1083/jcb.201102147.
25. Kalluri, R.; Weinberg, R.A. The Basics of Epithelial-Mesenchymal Transition. *J Clin Invest* 2009, *119*, (6), 1420–1428. DOI: 10.1172/JCI39104.
26. Carmeliet, P.; Jain, R.K. Principles and Mechanisms of Vessel Normalization for Cancer and Other Angiogenic Diseases. *Nat Rev Drug Discov* 2011, *10*, (6), 417–427. DOI: 10.1038/nrd3455.
27. De Palma, M.; Biziato, D.; Petrova, T.V. Microenvironmental Regulation of Tumour Angiogenesis. *Nat Rev Cancer* 2017, *17*, (8), 457–474. DOI: 10.1038/nrc.2017.51.
28. Hanahan, D.; Weinberg, R.A. Hallmarks of Cancer: The next Generation. *Cell* 2011, *144*, (5), 646–74. DOI: 10.1016/j.cell.2011.02.013; Available online: http://linkinghub.elsevier.com/retrieve/pii/S0092867411001279 http://www.ncbi.nlm.nih.gov/pubmed/21376230.
29. Quail, D.F.; Joyce, J.A. The Microenvironmental Landscape of Brain Tumors. *Cancer Cell* 2017, *31*, (3), 326–341. DOI: 10.1016/j.ccell.2017.02.009.
30. Arvanitis, C.D.; Ferraro, G.B.; Jain, R.K. The Blood-Brain Barrier and Blood-Tumour Barrier in Brain Tumours and Metastases. *Nat Rev Cancer* 2020, *20*, (1), 26–41. DOI: 10.1038/s41568-019-0205-x.